Gyre Therapeutics (NASDAQ:GYRE) & Immuron (NASDAQ:IMRN) Financial Analysis

Gyre Therapeutics (NASDAQ:GYRE) and Immuron (NASDAQ:IMRN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, profitability and institutional ownership.

Insider & Institutional Ownership

24.0% of Gyre Therapeutics shares are owned by institutional investors. Comparatively, 0.1% of Immuron shares are owned by institutional investors. 10.0% of Gyre Therapeutics shares are owned by company insiders. Comparatively, 7.0% of Immuron shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Gyre Therapeutics and Immuron”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$116.59 million	6.06	$5.03 million	($0.09)	-80.89
Immuron	$4.72 million	1.54	-$3.38 million	N/A	N/A

Gyre Therapeutics has higher revenue and earnings than Immuron.

Profitability

This table compares Gyre Therapeutics and Immuron’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-5.44%	3.13%	2.67%
Immuron	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings for Gyre Therapeutics and Immuron, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	2	0	2	0	2.00
Immuron	1	0	0	0	1.00

Gyre Therapeutics currently has a consensus price target of $17.00, indicating a potential upside of 133.52%. Given Gyre Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Gyre Therapeutics is more favorable than Immuron.

Risk and Volatility

Gyre Therapeutics has a beta of 2.03, meaning that its stock price is 103% more volatile than the S&P 500. Comparatively, Immuron has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.

Summary

Gyre Therapeutics beats Immuron on 11 of the 12 factors compared between the two stocks.

About Gyre Therapeutics

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

About Immuron

Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.